GT Biopharma, Inc.
GTBP
$0.42
-$0.01-2.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 53.53% | 138.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 65.43% | 123.53% | |||
| Operating Income | -65.43% | -123.53% | |||
| Income Before Tax | -639.60% | -117.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -639.60% | -117.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -639.60% | -117.31% | |||
| EBIT | -65.43% | -123.53% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -169.30% | -50.96% | |||
| Normalized Basic EPS | -124.56% | -52.86% | |||
| EPS Diluted | -169.30% | -50.96% | |||
| Normalized Diluted EPS | -124.56% | -52.86% | |||
| Average Basic Shares Outstanding | 229.33% | 42.17% | |||
| Average Diluted Shares Outstanding | 229.33% | 42.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 0.77% | -- | |||